Rare Disease

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Five things for pharma marketers to know: Monday, January 8, 2018

By

Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Wednesday, December 27, 2017

Five things for pharma marketers to know: Wednesday, December 27, 2017

By

Mallinckrodt to buy Sucampo for $1.2 billion; Amazon pushes digital advertising in 2018; WHO classifies gaming disorder as mental health condition

Five things for pharma marketers to know: Wednesday, December 20, 2017

Five things for pharma marketers to know: Wednesday, December 20, 2017

By

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

By

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

By

The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.

Five things for pharma marketers to know: Monday, December 11, 2017

Five things for pharma marketers to know: Monday, December 11, 2017

By

Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time

Five things for pharma marketers to know: Thursday, November 30, 2017

Five things for pharma marketers to know: Thursday, November 30, 2017

By

FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar

Five things for pharma marketers to know: Thursday, November 16, 2017

Five things for pharma marketers to know: Thursday, November 16, 2017

By

Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial

Five things for pharma marketers to know: Friday, November 10, 2017

Five things for pharma marketers to know: Friday, November 10, 2017

By

AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

By

The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.

Five things for pharma marketers to know: Wednesday, August 30, 2017

Five things for pharma marketers to know: Wednesday, August 30, 2017

By

Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Thursday, July 20, 2017

Five things for pharma marketers to know: Thursday, July 20, 2017

By

About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1

Five things for pharma marketers to know: Thursday, July 13, 2017

Five things for pharma marketers to know: Thursday, July 13, 2017

By

AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge

Nearly every $100,000 drug approved in the last three years was for a rare disease

Nearly every $100,000 drug approved in the last three years was for a rare disease

By

This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

By

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

4 Ways for Marketers To Differentiate Their Brands In The Rare-Disease Space

4 Ways for Marketers To Differentiate Their Brands In The Rare-Disease Space

Data analytics, relationship building, and improved patient support are the keys to differentiating your rare-disease drug brands, according to these four marketers.

Havas Health partners with data firm to find rare disease patients

Havas Health partners with data firm to find rare disease patients

By

The agency announced a partnership with Vencore Health Analytics to help pair rare disease patients with drugmakers.

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

By

The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.

Five things for pharma marketers to know: Friday, January 15, 2016

By

The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks

NORD and University of Maryland partner for rare-disease research training

The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

By

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

By

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

Horizon makes $1.1-billion rare-disease push

Horizon makes $1.1-billion rare-disease push

By

Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

By

The duo hope to begin testing a new treatment within three years.

Everyday Health buys rare-disease agency Cambridge BioMarketing

Everyday Health buys rare-disease agency Cambridge BioMarketing

By

The $38-million deal expands the reach of rare-disease campaigns.